دورية أكاديمية
Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
| العنوان: | Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer |
|---|---|
| المؤلفون: | Mukama, T, Fortner, RT, Katzke, V, Hynes, LC, Petrera, A, Hauck, SM, Johnson, T, Schulze, M, Schiborn, C, Rostgaard-Hansen, AL, Tjønneland, A, Overvad, K, Pérez, MJS, Crous-Bou, M, Chirlaque, M-D, Amiano, P, Ardanaz, E, Watts, EL, Travis, RC, Sacerdote, C, Grioni, S, Masala, G, Signoriello, S, Tumino, R, Gram, IT, Sandanger, TM, Sartor, H, Lundin, E, Idahl, A, Heath, AK, Dossus, L, Weiderpass, E, Kaaks, R |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2021 |
| المجموعة: | Imperial College London: Spiral |
| مصطلحات موضوعية: | Science & Technology, Life Sciences & Biomedicine, Oncology, TRIAL, ADAM Proteins, Biomarkers, Tumor, Blood Proteins, CA-125 Antigen, Carcinoma, Ovarian Epithelial, Case-Control Studies, Early Detection of Cancer, Female, Folate Receptor 1, Humans, Membrane Proteins, Ovarian Neoplasms, ROC Curve, Oncology & Carcinogenesis, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services |
| الوصف: | Background CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. Methods In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Results Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Conclusion Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0007-0920 |
| العلاقة: | British Journal of Cancer; http://hdl.handle.net/10044/1/94083Test |
| DOI: | 10.1038/s41416-021-01697-z |
| الإتاحة: | https://doi.org/10.1038/s41416-021-01697-zTest http://hdl.handle.net/10044/1/94083Test |
| حقوق: | © The Author(s) 2022 ; http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.CA3268E2 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00070920 |
|---|---|
| DOI: | 10.1038/s41416-021-01697-z |